PHYLAX IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SYSTEM
Biotronik, Inc. · Decision date Oct 27, 1998
What did the FDA approve?
FDA records P980023 as an original PMA application. The recorded decision is approval, dated Oct 27, 1998.
FDA approval order statement
Approval for the Phylax Implantable Cardioverter Defibrillator (ICD) System: a) ICD PUlse Generator - Phylax XM ICD, model number 121491; Phylax XM Active Housing ICD, model number 121492; Phylax XM Replacement ICD, model number 121162 and mycroPhylax ICD, model number 121493; b) ICD Lead - SPS 75 Lead System, model number 120398; SL-ICD Lead Systems (SL-ICD 75/13, model number 120395, SL-ICD 75/16, model number 120396, SL-ICD 75/18, model number 120397, SL-ICD 100/13, model number 116414, SL-ICD 100/16, model number 118375, SL-ICD118375, SL-ICD 100/18, model number 119077); Kainox SL Lead Systems (Kainox SL 75/13, model number 124219, Kainox SL 75/16, model number 124218, Kainox SL 75/18, model number 124217, Kainox SL 100/13, model number 124238, Kainox SL 100/16, model number 124239, Kainox SL 100/18, model number 124240); Kainox RV 75 Lead System, model number 124005; and (c) Programming and Monitoring System - TMS 1000 Tachyarrhythmia Monitoring System, and Software Module SWM 1000 F00I01. This device is indicated for use in patients who are at risk of sudden death due to ventricular arrhythmias and have experienced one of the following situations: survival of at least one episode of cardiac arrest (manifested by a loss of consciousness) due to a ventricular tachyarrhythmia; or recurrent poorly tolerated sustained ventricular tachycardia (VT). Note: the clinical outcome for hemodynamically stable VT patients is not fully know. Safety and effectiveness studies for this indication have not been conducted.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 27, 1998
Regulatory record facts
- Identifier
- P980023
- Regulatory pathway
- Premarket approval application
- Applicant
- Biotronik, Inc.
- Product code
- LWS
- Decision code
- APPR
- Decision date
- Oct 27, 1998
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable cardioverter defibrillator (non-CRT).
- Applicant
- Biotronik, Inc.
- Product code
- LWS
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P980023 received
Application receipt date recorded by FDA.
P980023 · FDA decision
APPR
P980023/S150 · Related supplement
Pamira S 60; Pamira S 65; Pamira S 75; Pamira SD 60/16; Pamira SD 65/16; Pamira SD 65/18; Pamira SD 75/18; Pamira S DX 6
P980023/S146 · Related supplement
Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva
P980023/S140 · Related supplement
Ilivia Neo 7 VR-T DX 429530; Intica Neo 7 VR-T DX 429559; Intica Neo 5 VR-T DX 429569
P980023/S151 · Related supplement
Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva
P980023/S149 · Related supplement
Acticor Sky VR-T 481989; Rivacor Sky VR-T 481984; Rivacor Rise VR-T 482020; Rivacor Aura VR-T 482015; Acticor Sky VR-T D
P980023/S152 · Related supplement
Ilivia Neo 7 VR-T DX DF-1 ProMRI, Ilivia Neo 7 VR-T DF-1 ProMRI, Intica Neo 7 VR-T DX DF-1 ProMRI, Intica Neo 7 VR-T DF-
P980023/S153 · Related supplement
Ilivia Neo 7 VRT DX, Intica Neo 7 VRT DX, Intica Neo 5 VRT DX, Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Ri
Timeline entries are records held by MedtechLedger for P980023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA supplement | Sep 10, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code LWS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA | |
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICDP980016/S967 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 5, 2026 | FDA | |
| BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P980023
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




